Chimerix, a Durham, N.C.-based biotechnology company developing orally-available antiviral therapeutics, has appointed Michelle Berrey, MD, MPH, as chief medical officer.

Prior to joining Chimerix, Berrey served as CMO at Pharmasset, a company that focused on the development of nucleotide analogs for the treatment of hepatitis C, from 1997 until its acquisition by Gilead Sciences in January 2012. Her experience includes the design, early development, medical governance, clinical strategy and product life cycle management of antiviral products.

Berrey also previously served as vice president, viral diseases, clinical pharmacology and discovery medicine at GlaxoSmithKline, where she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses and hepatic fibrosis.